StatusBoth components individually registered as prescription drugs in Russia only; no fixed combination is registered anywhereBest evidenceE5Sources checked2026-09-18
Selank / Semax pairs two separately registered Russian nootropic nasal drops from the same research lineage. No study has tested the two together, and Selank on its own has no human trial in the literature searched for this site at all, only rat and mouse pharmacology.
What is in it
Amounts most commonly stated by suppliers. Not standardised.
This name is not standardised. Different suppliers use it for different combinations and different ratios. A product sold under this name may not match what is described here. Check the actual composition of anything you are looking at.
Evidence below concerns the combination itself. Research on each component is on that component’s own entry.
What it is
Selank / Semax is a name applied to combining two separately registered Russian nootropic drugs, sold as intranasal drops, in the same research-peptide routine. Both were developed from the same Pro-Gly-Pro-tripeptide-extension approach at Russian institutes: Semax extends a fragment of ACTH, Selank extends the immune peptide tuftsin. They are not co-formulated in a single Russian pharmaceutical product; each is its own registered drug, and “stacking” them is a research-community practice, not a manufacturer’s combination product.
What is known about the combination
No study, animal or human, testing Selank and Semax administered together was located for this entry. Each has its own separate entry on this site, and each has its own separate, and very different, evidence base: Semax has real, if methodologically limited, published human trials in post-stroke rehabilitation; Selank, on the search run for this entry, has no published human trial of any kind, only rat and mouse pharmacology.
The rationale usually offered for combining them, that Semax contributes cognitive and neuroprotective effects while Selank contributes anxiolytic and calming effects, is a plausibility argument built from each compound’s own separate literature, not a tested claim about the pair.
What the component evidence actually says
Both share on this site are worth reading before this pairing makes sense. In brief:
Semax’s human evidence is limited to post-stroke rehabilitation trials that were not blinded, placebo-controlled studies by Western standards, and none has been independently replicated outside Russia.
Selank has no human trial located in the search run for this site’s entry on it at all; every published finding is in rats or mice.
Stacking a compound with limited human evidence together with a compound that has none does not average out to something in between. It combines two separate sets of open questions.
What is not known
Whether combining the two produces any effect, in any direction, that either alone would not. No study of the pair exists.
Whether the two are chemically compatible when mixed in the same nasal-drop solution outside their separate, manufacturer-controlled formulations. No stability data for a mixed solution was located.
Everything already unknown about each component separately, including whether Selank’s effects, entirely rodent so far, translate to a human being at all.
Regulatory status
Both Semax and Selank are registered prescription drugs in Russia individually. Neither is approved in the United States, the European Union or any other major jurisdiction, and no fixed combination product of the two is registered anywhere in the sources reviewed for this entry.
What is not known
Whether combining the two produces any effect, in any direction, that either alone would not. No study of the pair exists, in any species.
Whether the two are chemically stable together outside their separate manufacturer formulations. No mixed-solution stability data was located.
Everything already unknown about each component separately, including whether Selank’s entirely rodent evidence base translates to a human being at all, and whether Semax’s stroke-rehabilitation findings would replicate under blinded conditions.
Doses used in published research
No published study has administered this compound to a human being, so no dose appears in the literature and none has been established.
Amounts above record what a named source reported administering in a study. They are not a recommendation, not a protocol, and not instructions.
Converting a vial and a syringe into a draw volume is a separate, mechanical question from what amount to use. The reconstitution calculator does that arithmetic for peptide, HCG, and HGH vials.
What circulates E5
Figures reported online. Not dosing, not verified, not endorsed.
Reported use
Route
Amount reported
Frequency
Reported length
Cognitive and calming stack, general
Intranasal
Component doses as described on each compound's own entry
One to three times daily
Often cycled, days to a few weeks
Circulating material for this stack generally directs the reader to each component’s own separate dosing figures rather than proposing a combined-product dose, consistent with the fact that these are two separately manufactured drugs, not one blended product. See each compound’s own entry for the comparison between its circulating figure and its own studied record; for Semax that record is post-stroke rehabilitation at doses far above the circulating cognitive-use figure, and for Selank there is no human studied record to compare against at all.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.